Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prestige Consumer Healthcare Inc. filings document material events for an operating consumer healthcare company, including 8-K disclosures on quarterly and year-to-date operating results, financial condition and Regulation FD investor presentations. The filings also cover material agreements, capital-structure matters, governance topics and shareholder voting matters tied to the company’s public-company reporting.
These records frame Prestige’s disclosures around its portfolio of over-the-counter healthcare brands, retail distribution markets, and product or regulatory matters when they are material to the business.
Prestige Consumer Healthcare develops, markets and distributes over-the-counter health and personal care brands across North America and select international markets. North American OTC Healthcare generated 83.9% of net revenues in 2026, with International OTC Healthcare contributing 16.1%.
Major brands such as BC and Goody’s, Chloraseptic, Clear Eyes, Compound W, Dramamine, Fleet, Gaviscon, Monistat, Nix and Summer’s Eve give the company leading positions in many niche categories. In 2026, about 63.7% of total revenues came from brands holding a number one market position, and approximately 83.5% of revenues came from major brands.
The company grows through organic innovation and acquisitions, including the 2026 purchase of sterile ophthalmic manufacturer Pillar5 and a signed agreement to acquire OTC brands such as Breathe Right and Dimetapp. Key risks include heavy reliance on third-party manufacturers, concentrated sourcing from one supplier that produced about 21% of gross revenues, inflationary input costs, and customer concentration, with Walmart and Amazon representing roughly 20% and 15% of 2026 gross revenues. Prestige also faces regulatory, supply chain and sustainability-related pressures that could affect margins and product availability.
Prestige Consumer Healthcare Inc. executive Christine Sacco, the company’s CFO and COO, reported a tax-withholding disposition of 1,091 shares of common stock at a price of $55.09 per share. This adjustment reflects a correction to an earlier inadvertent error and leaves her holding 57,374 shares directly.
Prestige Consumer Healthcare reported fiscal 2026 results and agreed to acquire LaCorium Health for approximately $150 million in cash. Full-year revenue was $1,088.7 million, down 4.3% from the prior year, as limited Clear Eyes supply and shipping disruptions weighed on sales, especially in Eye & Ear Care.
Fiscal 2026 net income was $190.3 million with diluted EPS of $3.91, while non-GAAP adjusted diluted EPS was $4.38. Free cash flow grew to $246.4 million, and the company repurchased 2.3 million shares for about $156 million, ending the year with net debt of roughly $0.9 billion and a 2.6x covenant-defined leverage ratio.
LaCorium generated about $40 million in trailing twelve-month revenue through February 28, 2026 and is expected to deliver roughly $12 million in EBITDA including anticipated synergies. For fiscal 2027, Prestige guides to revenue of $1,100–$1,121 million, organic growth of 1%–3%, adjusted diluted EPS of $4.42–$4.51, and free cash flow of $250 million or more, excluding acquisition impacts.
Prestige Consumer Healthcare Inc. Senior VP Operations Jeffrey Zerillo reported an open-market sale of 351 shares of common stock on May 11, 2026 at $52.28 per share. After this transaction, he directly owns 41,810 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Senior VP of Operations Jeffrey Zerillo reported an open-market sale of 305 shares of common stock at $54.36 per share. A separate transaction shows 351 shares withheld at $54.59 per share to cover tax obligations, a non-market event.
After these transactions, Zerillo directly holds 42,161 shares of Prestige Consumer Healthcare common stock, indicating that the reported sale represents only a small portion of his remaining stake.
Prestige Consumer Healthcare CFO & COO Christine Sacco reported a routine tax-related share disposition. On May 7, 991 shares of common stock were withheld at $54.59 per share to cover tax obligations, a non-market transaction. After this, she directly owns 71,636 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. Chief Executive Officer Ronald M. Lombardi reported a routine share withholding for taxes. On May 7, 2026, 2,543 shares of common stock were disposed of at $54.59 per share as a tax-withholding disposition, rather than an open-market sale. Following this transaction, Lombardi directly holds 373,465 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare EVP Mekhail Adel reported a routine tax-related share disposition. On May 7, 2026, 487 shares of common stock were withheld at $54.59 per share to cover tax obligations. After this transaction, Adel directly holds 25,703 shares of Prestige Consumer Healthcare common stock.
PBH Rule 144 notice filed to offer 351 shares of Common Stock. The filing shows 351 shares tied to Restricted Stock Vesting on 05/07/2026 and lists Fidelity Brokerage Services LLC as the broker. The record also lists recent sales by Jeffrey Zerillo totaling 2,858 shares across February and May 2026 with associated dollar figures shown in the excerpt.
Prestige Consumer Healthcare Senior VP Operations Jeffrey Zerillo reported an open-market sale of 1,207 shares of common stock at $54.99 per share. In a separate transaction, 307 shares were disposed of to satisfy tax withholding obligations at $55.75 per share. Following these transactions, he directly holds 44,027 shares after the tax-withholding disposition and 42,820 shares after the open-market sale, indicating these trades involved a relatively small portion of his reported direct holdings.